A conversation with Sherlock Biosciences CEO, Rahul Dhanda
Founded in 2019 with technologies developed at the Broad Institute & Harvard University’s Wyss Institute, Sherlock has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its Sherlock™ CRISPR SARS-CoV-2 kit for the detection of the virus that causes #COVID19, providing results in approximately one hour.
Rahul Dhanda is a founder and the President & CEO of Sherlock Biosciences. He serves on the company’s Board of Directors. Most recently Mr. Dhanda spent 10 years at T2 Biosystems as senior vice president of corporate development and marketing, helping grow the company from an early-stage, venture-backed startup to a commercial, publicly-traded leader in infectious disease diagnostics. He had an expansive role leading the company’s strategy, marketing, product management and all corporate deal activity, the latter bringing $40+ million in funding to the company. Prior to joining T2 Biosystems, Mr. Dhanda worked in Boston Scientific’s urology division, leading a team responsible for $100+ million in annual revenue.
Pre-registration required.
Unless otherwise specifically stated in relation to each and any of the events listed on this page, the MLSC does not host or sponsor these events. The MLSC has no oversight or responsibility for the venue, content or host-organization related to these events. The MLSC has no affiliation with the organizations listing events or with the events, and provides this content and information as a convenience to visitors to the MLSC website.
